↓ Skip to main content

Dove Medical Press

Article Metrics

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

Overview of attention for article published in Drug Design, Development and Therapy, March 2015
Altmetric Badge

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
36 Mendeley
Title
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Published in
Drug Design, Development and Therapy, March 2015
DOI 10.2147/dddt.s82007
Pubmed ID
Authors

Baoan Chen, Runzhe Chen

Abstract

Brentuximab vedotin is a promising antibody-drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin's lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 17%
Researcher 6 17%
Student > Ph. D. Student 5 14%
Student > Master 4 11%
Student > Doctoral Student 3 8%
Other 4 11%
Unknown 8 22%
Readers by discipline Count As %
Medicine and Dentistry 10 28%
Chemistry 4 11%
Biochemistry, Genetics and Molecular Biology 2 6%
Neuroscience 2 6%
Computer Science 2 6%
Other 7 19%
Unknown 9 25%